Know Cancer

or
forgot password

Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer


Inclusion Criteria:



1. Patients must have histologically-confirmed non-small cell lung cancer
(adenocarcinoma, squamous, large cell and undifferentiated). Mixed small cell and
non-small histologies are excluded.

2. Patients with completely resected (R0) stage IB, II, and select III NSCLC. The
following stages are eligible:

IB T2 N0 IIA T1 N1 IIB T2 N1 IIB T3 N0 IIIA T3 N1

- Bronchioalveolar carcinoma that presents as a single, solitary discrete nodule
or mass may be included

- Patients determined to have N2 disease, that was not apparent radiologically
preoperatively (and completely resected) can be included.

3. Complete surgical resection defined as the appropriate pulmonary parenchymal
resection including lobectomy, bilobectomy, sleeve lobectomy, and pneumonectomy with
histologically confirmed negative bronchial margins. Patients treated by
segmentectomy or wedge resection are not eligible for this study. Additionally all
patients must have had either a mediastinal node dissection or at least, sampling of
2 mediastinal nodal stations (levels 4,7,and 9 for right-sided tumors, and levels
5,6,7, and 9 for left-sided tumors are suggested.)

4. No evidence of metastatic disease

5. ANC >= 1500, platelets >= 100,000 and hemoglobin >= 10.0.

6. Total bilirubin <= ULN. AST and ALT and alkaline phosphatase must be WNL

7. Serum creatinine <= 1.5mg/dl (If greater than 1.5, the creatinine clearance,
calculated according to the Cockroft-Gault formula, must be >= 50ml/min).

8. Patients may have had no previous chemotherapy, radiation therapy, angiogenesis
inhibitor, or tyrosine kinase inhibitor for non-small cell lung cancer.

9. Patients must be able to understand the nature of this study and give written
informed consent.

10. Age >= 18 years

11. Ability to start treatment between 8 and 12 weeks following surgery.

12. Ability to take oral medication.

Exclusion Criteria:

1. Patients with preoperative radiologic evidence of N2 disease by either PET or CT scan
(i.e. radiological evidence of metastasis to ipsilateral mediastinal and subcarinal
nodes) that is confirmed as N2 disease histologically are excluded. - PLEASE SEE
EXCEPTION in section 3.1.2 of protocol

2. Mixed small cell and non-small cell histologies

3. Pulmonary carcinoid tumors

4. Positive bronchial margins

5. History of prior malignancy within 5 years with the exception of skin cancer or
cervical carcinoma in situ.

6. Women who are pregnant (positive pregnancy test) or breast-feeding. Subjects of
childbearing potential or with partners of childbearing potential (women and men)
must use effective birth control measures during treatment.

7. Treatment with a non-approved or investigational drug within 30 days before day 1 of
trial treatment.

8. Patients with seizures not controlled with standard medical therapy.

9. Patients with active infection requiring parenteral antibiotics

10. Patients who have had major surgical procedure, open biopsy, or significant traumatic
injury within 8 weeks of beginning study treatment or anticipation of need for major
surgical procedure during the course of the study

11. Fine needle aspiration, core biopsy or other minor surgical procedure (excluding
placement of a vascular access device) within 7 days of beginning study treatment.

12. Patients receiving thrombolytic therapy within 10 days of starting study treatment
are also ineligible. Patients may receive prophylactic anticoagulation therapy, 1 mg
coumadin daily for port clot prophylaxis.

13. Patients with proteinuria at screening as demonstrated by either:

- Urine protein creatinine (UPC) ratio >= 1.0 at screening OR

- Urine dipstick for proteinuria >= 2+ (patients discovered to have >= 2+
proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine
collection and must demonstrate >= 1 g of protein in 24hours to be eligible).

14. Patients with serious nonhealing wound, ulcer, or bone fracture.

15. Patients with evidence of bleeding diathesis or coagulopathy.

16. Patients with history of hemoptysis defined as bright red blood of ½ teaspoon or more
per episode) within 8 weeks prior to study treatment.

17. History of myocardial infarction or unstable angina within 6 months of beginning
study treatment.

18. Inadequately controlled hypertension (defined as systolic blood pressure > 150 and
/or diastolic blood pressure > 100 mmHg on antihypertensive medications).

19. New York Heart Association (NYHA) grade II or greater CHF.

20. Serious cardiac arrhythmia requiring medication.

21. Symptomatic peripheral vascular disease.

22. History of stroke or transient ischemic attack within 6 months prior to beginning
bevacizumab.

23. Any prior history of hypertensive crisis or hypertensive encephalopathy.

24. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to beginning study treatment.

25. ECOG Performance status > 1.

26. Peripheral neuropathy> grade 1.

27. Known hypersensitivity to any component of study drugs including platinum or to
drugs formulated with polysorbate 80.

28. Impaired oral absorption.

29. Inability to comply with study and/or follow-up procedures.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Disease-free survival

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

David Spigel, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Institutional Review Board

Study ID:

SCRI LUN 142

NCT ID:

NCT00621049

Start Date:

December 2007

Completion Date:

May 2014

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Resected
  • Carboplatin
  • Docetaxel
  • Bevacizumab
  • Erlotinib
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Northeast Arkansas ClinicJonesboro, Arkansas  72401-3125
Florida Cancer SpecialistsFort Myers, Florida  33901
Northeast Georgia Medical CenterGainesville, Georgia  30501
New Mexico Oncology Hematology ConsultantsAlbuquerque, New Mexico  87102
Medical Oncology Associates of AugustaAugusta, Georgia  30901
Peninsula Cancer InstituteNewport News, Virginia  23601
Center for Cancer and Blood DisordersBethesda, Maryland  20817
Cancer Care of Western North CarolinaAsheville, North Carolina  28801
Portsmouth Regional HospitalPortsmouth, New Hampshire  03802
Gulfcoast Oncology AssociatesSt. Petersburg, Florida  33705
St. Louis Cancer CareChesterfield, Missouri  63017
Tennessee Oncology, PLLCClarksville, Tennessee  37043
Hematology Oncology Life CenterAlexandria, Louisiana  71301
Jackson Oncology AssociatesJackson, Mississippi  39202
Wellstar Cancer ResearchMarietta, Georgia  30060
Oncology Hematology CareCincinnati, Ohio  45242
Providence Medical GroupTerre Haute, Indiana  47802
Baptist Hospital EastLouisville, Kentucky  40207
Norton Cancer InstituteLouisville, Kentucky  40207
Hematology Oncology Clinic, LLPBaton Rouge, Louisiana  70809
Hematology Oncology Associates of Northern NJMorristown, New Jersey  07960
Chattanooga Oncology Hematology AssociatesChattanooga, Tennessee  37404
Associates in Hematology OncologyChattanooga, Tennessee  37404
Nebraska Methodist Cancer CenterOmaha, Nebraska  68114
Northeast Alabama Medical CenterAnniston, Alabama  36207
RHHP/Hope Cancer CenterTerre Haute, Indiana  47802